دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell DiseaseA Randomized Clinical Trial
James F. Casella, MD; Bruce A. Barton, PhD; Julie Kanter, MD; et al.
doi : 10.1001/jama.2021.3414
JAMA. 2021;325(15):1513-1523.
This phase 3 trial examines the effectiveness of poloxamer 188 in reducing the duration of painful vaso-occlusive episodes in children and adults with sickle cell disease compared with placebo.
Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19
The Writing Committee for the COMEBAC Study Group
doi : 10.1001/jama.2021.3331
JAMA. 2021;325(15):1525-1534.
This French cohort study describes coronavirus disease sequelae at 4 months in patients hospitalized for COVID-19 between March and May 2020, including assessment of respiratory, cognitive, and functional symptoms and test and imaging findings.
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
Kathryn E. Stephenson, MD, MPH; Mathieu Le Gars, PhD; Jerald Sadoff, MD; et al.
doi : 10.1001/jama.2021.3645
JAMA. 2021;325(15):1535-1544.
This randomized trial compares the immunogenicity of a SARS-CoV-2 Ad26.COV2.S vaccine at high vs low vs no dose (placebo) in humans, including the kinetics, magnitude, and phenotype of coronavirus spike-specific humoral and cellular immune responses.
SARS-CoV-2 Positivity on or After 9 Days Among Quarantined Student Contacts of Confirmed Cases
Eric J. Nelson, MD, PhD, MS; Sarah L. McKune, PhD, MPH; Kathleen A. Ryan, MD; et al.
doi : 10.1001/jama.2021.2392
JAMA. 2021;325(15):1561-1562.
This study describes coronavirus test positivity rates among elementary, middle, and high school student contacts of confirmed COVID-19 cases in a Florida county where schools required a negative test on day 9 before return to school on day 10.
Acute Allergic Reactions to mRNA COVID-19 Vaccines
Kimberly G. Blumenthal, MD, MSc; Lacey B. Robinson, MD, MPH; Carlos A. Camargo Jr, MD, DrPH; et al.
doi : 10.1001/jama.2021.3976
JAMA. 2021;325(15):1562-1565.
This study examines the incidence of acute allergic reactions to mRNA COVID-19 vaccine administrations in health care employees in Massachusetts.
CDC Interim Recommendations for Fully Vaccinated PeopleAn Important First Step
Athalia Christie, MIA; Sarah A. Mbaeyi, MD; Rochelle P. Walensky, MD
doi : 10.1001/jama.2021.4367
JAMA. 2021;325(15):1501-1502.
This Viewpoint summarizes CDC activity recommendations for individuals fully vaccinated against SARS-CoV-2 infection, including resumption of low-risk gatherings among vaccinated people and maintenance of public health measures in activities involving unvaccinated people.
Incentivizing Vaccination UptakeThe “Green Pass” Proposal in Israel
Rachel Wilf-Miron, MD, MPH; Vicki Myers, PhD; Mor Saban, PhD
doi : 10.1001/jama.2021.4300
JAMA. 2021;325(15):1503-1504.
This Viewpoint explains the “green pass” program in Israel to encourage residents to seek COVID-19 vaccination, with incentives including access to social, cultural, and sports events and gyms, hotels, and restaurants as well as exemption from quarantine after travel or exposure to an individual with SARS-CoV-2 infection.
Precision Dosing: A Clinical and Public Health Imperative
Kimberly Maxfield, PhD; Issam Zineh, PharmD, MPH
doi : 10.1001/jama.2021.1004
JAMA. 2021;325(15):1505-1506.
This Viewpoint describes the concept of precision drug dosing, which would maximize drug benefit and minimize harm for each patient, and reviews the scientific, regulatory, technical, and practical infrastructures that would need to be in place for the idea to become reality in clinical practice settings.
Medications in Single-Dose Vials and Implications of Discarded Injectable DrugsA National Academies Report
Edward H. Shortliffe, MD, PhD; Gary H. Lyman, MD, MPH; Francis K. Amankwah, MPH
doi : 10.1001/jama.2021.2414
JAMA. 2021;325(15):1507-1508.
This Viewpoint summarizes a 2021 NASEM report that makes policy recommendations to reduce systems inefficiencies that lead to discarded medications in the US, including development of standards to allow safe use of single-dose vials across multiple patients, and use of payment models to reimburse treatment episodes rather than drug vial volume or cost.
Start With All the Little Things
Alexander Zider, MD
doi : 10.1001/jama.2021.4885
JAMA. 2021;325(15):1509-1510.
In this narrative medicine essay, a pulmonologist learns about process improvement from his father, an engineer, who drew up a list of 50 improvements he noted during his hospitalizations for prostate cancer.
Outcomes for Patients Following Hospitalization for COVID-19
Hallie C. Prescott, MD, MSc
doi : 10.1001/jama.2021.3430
JAMA. 2021;325(15):1511-1512.
Oral Antiplatelet Therapy After Acute Coronary SyndromeA Review
Hassan Kamran, MD; Hani Jneid, MD; Waleed T. Kayani, MD; et al.
doi : 10.1001/jama.2021.0716
JAMA. 2021;325(15):1545-1555.
This narrative review summarizes oral antiplatelet therapy and specifically addresses the effects of dual antiplatelet therapy for patients with acute coronary syndrome who have not taken anticoagulants.
Management of Acute Coronary Syndromes in Patients Without Persistent ST-Segment Elevation
Rajeev Anchan, MD; Adam S. Cifu, MD; Jonathan Paul, MD
doi : 10.1001/jama.2021.2744
JAMA. 2021;325(15):1556-1557.
This JAMA Clinical Guidelines Synopsis summarizes the European Society of Cardiology’s 2020 recommendations for management of patients with non–ST-segment elevation acute coronary syndromes.
Recurrent Hematochezia in a Returning Traveler
Shana E. Gleeson, MD; Xuchen Zhang, MD, PhD; Marwan M. Azar, MD
doi : 10.1001/jama.2021.0368
JAMA. 2021;325(15):1558-1559.
A 28-year-old man who while traveling swam in the upper Nile River in Uganda developed intermittent diarrhea and hematochezia but no vomiting, fever, or weight loss; physical examination and laboratory findings were unremarkable, and colonoscopy with biopsy showed rectal granulomas containing oval-shaped features with lateral spines. What is the diagnosis and what would you do next?
Poloxamer 188 for Sickle Cell Disease
Jody Zylke, MD
doi : 10.1001/jama.2021.3399
JAMA. 2021;325(15):1524.
The Push for Timely Follow-up After Abnormal At-home Colon Cancer Screening Results
Mary Chris Jaklevic, MSJ
doi : 10.1001/jama.2021.2018
JAMA. 2021;325(15):1492-1493.
This Medical News article describes a call for guidelines to establish a standard time interval for follow-up colonoscopy after an abnormal fecal test result for colon cancer screening.
Primary Care Health Coaches Help Low-Income Patients Curb Obesity
Mary Chris Jaklevic, MSJ
doi : 10.1001/jama.2021.3165
JAMA. 2021;325(15):1494-1495.
This Medical News article describes a trial of intensive behavioral interventions at primary-care clinics for low-income patients with obesity.
Pathway Eased for Serial COVID-19 Screening Tests
Mary Chris Jaklevic, MSJ
doi : 10.1001/jama.2021.5391
JAMA. 2021;325(15):1499.
Molecular COVID-19 Test Gains First EAU for At-home Use
Mary Chris Jaklevic, MS
doi : 10.1001/jama.2021.5121
JAMA. 2021;325(15):1499.
Breaks in Ankle Implant Are a Cause for Concern
Mary Chris Jaklevic, MSJ
doi : 10.1001/jama.2021.5393
JAMA. 2021;325(15):1499.
Price Transparency—Promise and Peril
Sherry Glied, PhD
doi : 10.1001/jama.2021.4640
JAMA. 2021;325(15):1496-1497.
Preventable Vision Loss Affects Millions Globally
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.4494
JAMA. 2021;325(15):1498.
Costly Hearing Loss Requires Greater Global Attention
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.5498
JAMA. 2021;325(15):1498.
COVID-19 in Clinicians—More Cases in Women, More Deaths in Men
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.5500
JAMA. 2021;325(15):1498.
Nontuberculous Mycobacterial Infections
Angel N. Desai, MD, MPH; Rocio Hurtado, MD, DTM&H
doi : 10.1001/jama.2020.19062
JAMA. 2021;325(15):1574.
This JAMA Patient Page describes the risk factors, symptoms, diagnosis, treatment, and prevention measures for nontuberculous mycobacterial infections.
The Johnson & Johnson Vaccine for COVID-19
Edward H. Livingston, MD; Preeti N. Malani, MD, MSJ; C. Buddy Creech, MD, MPH
doi : 10.1001/jama.2021.2927
JAMA. 2021;325(15):1575.
This JAMA Patient Page explains how the Johnson & Johnson COVID-19 vaccine, likely to be the third SARS-CoV-2 vaccine approved for widespread use, uses an adenovirus 26 vector to deliver coronavirus DNA to host cells to produce spike proteins and safely and effectively induce immunity.
Fractional Flow Reserve Treatment and Major Adverse Cardiac Events in Patients With Coronary Artery Disease
Gianluca Rigatelli, MD, PhD; Marco Zuin, MS
doi : 10.1001/jama.2021.1435
JAMA. 2021;325(15):1565.
Fractional Flow Reserve Treatment and Major Adverse Cardiac Events in Patients With Coronary Artery Disease—Reply
Maneesh Sud, MD; Jiming Fang, PhD; Dennis T. Ko, MD, MSc
doi : 10.1001/jama.2021.1441
JAMA. 2021;325(15):1565-1566.
Quantifying the Effect of Lower vs Higher Positive End-Expiratory Pressure on Ventilator-Free Survival in ICU Patients
Zachary R. McCaw, PhD; Lu Tian, ScD; Lee-Jen Wei, PhD
doi : 10.1001/jama.2021.1700
JAMA. 2021;325(15):1566-1567.
Quantifying the Effect of Lower vs Higher Positive End-Expiratory Pressure on Ventilator-Free Survival in ICU Patients—Reply
Ary Serpa Neto, MD, MSc, PhD; Anna Geke Algera, MD; Marcus J. Schultz, MD, PhD; et al.
doi : 10.1001/jama.2021.1703
JAMA. 2021;325(15):1567-1568.
